Loading
AgonOx
AgonOx is a Portland company growing a patient's own tumour-fighting immune cells for re-infusion, selecting only the fraction that recognises the tumour. Its therapy, AGX-148, is in an early trial in solid tumours.
Also called: AgonOx, Inc.
Overview
AgonOx, Inc. develops tumour-infiltrating lymphocyte (TIL) therapy that isolates and expands the CD39-positive, CD103-positive subset of a patient's CD8 TIL, which the company describes as the tumour-reactive fraction. Its lead programme AGX-148 is in phase 1 in solid tumours, with further cell therapy programmes in IND-enabling studies. AgonOx sponsors NCT05902520, a phase 1 trial of these CD8 TIL in adults with solid tumours, which ClinicalTrials.gov lists as active and not recruiting. A 2026 National Cancer Institute SBIR award funds enriching and expanding tumour-reactive CD8 T cells to treat breast cancer.
Headquarters
Portland, OR, US
Scorecard
All companies#703of 1706 companies, score 3
- phase 1/2 +1
- modalities +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR (R44) award 1R44CA314796-01: Enriching and expanding tumor-reactive CD8 T-cells to treat breast cancer | 2026 | $978K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1Phase 1Autologous tumour-infiltrating lymphocyte therapy
AGX-148 is an experimental cell therapy from AgonOx made from the tumour-recognising immune cells in a patient's own tumour. It is in an early trial in solid tumours.
Notes
- Company website, the NIH RePORTER record and the ClinicalTrials.gov record for NCT05902520 read on 4 November 2026. NCT05902520 is not yet a trial record in OnCo.
Connected
5cancers
fronts
technologies
drugs
Phase 1Autologous tumour-infiltrating lymphocyte therapy
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
agonox.com · 1
ClinicalTrials.gov · 1
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/